Did local teicoplanin delivery systems inhibit or aggravate implant-related infection?
Cai
Xun-Zi
XZ
Jin
Ai-Dong
AD
Yan
Shi-Gui
SG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial / Q000706:statistics & numerical data; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D020007:Implants, Experimental; D007595:Joint Prosthesis / Q000009:adverse effects / Q000382:microbiology; D010019:Osteomyelitis / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D011474:Prosthesis Design; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000517:prevention & control; D013530:Surgical Wound Infection / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D017334:Teicoplanin / Q000494:pharmacology*; D013978:Tibial Fractures / Q000382:microbiology / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017334:Teicoplanin